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Chagas disease has a high incidence in Mexico and other Latin American countries. Because one of the most
important known methods of prevention is vector control, which has been effective only in certain areas of South
America, the development of a vaccine to protect people at risk has been proposed. In this study, we assessed the
cellular and humoral immune response generated following immunization with pBCSP and pBCSSP4 plasmids
containing the genes encoding a trans-sialidase protein (present in all three forms of T. cruzi) and an amastigote
specific glycoprotein, respectively, in a canine model. Thirty-five beagle dogs were divided randomly into 5 groups
(n = 7) and were immunized twice intramuscularly with 500 μg of pBCSSP4, pBCSP, pBk-CMV (empty plasmid) or
saline solution. Fifteen days after the last immunization the 4 groups were infected intraperitoneally with 500 000
metacyclic trypomastigotes. The fifth group was unimmunized/infected. The parasitaemia in the immunized/
infected dogs was for a shorter period (14 vs. 29 days) and the parasite load was lower. The concentration of IgG1
(0.612 ± 0.019 O.D.) and IgG2 (1.167 ± 0.097 O.D.) subclasses was measured (absorbance) 15 days after the last
immunization with both recombinant plasmids, the majority of which were IgG2. The treatment of parasites using
the serum from dogs immunized with pBCSP and pBCSSP4 plasmids produced 54% (± 11.8) and 68% (± 21.4)
complement-mediated lysis, respectively. At 12 h post immunization, an increase in cytokines was not observed;
however, vaccination with pBCSSP4 significantly increased the levels of IFN-γ and IL-10 at 9 months post-infection.
The recombinant plasmid immunization stimulated the spleen cell proliferation showing a positive stimulatory
index above 2.0. In conclusion, immunization using both genes effectively induces a humoral and cellular immune
response.Introduction
Chagas’ disease, caused by the parasite protozoan
Trypanosoma cruzi, is estimated to affect 10 million
people in the Americas [1]. To date, the most important
prevention method is to campaign for the elimination of
the vector; however, these efforts have achieved only par-
tial control of the disease. There is a need for an im-
munoprotective vaccine to decrease the morbidity and
mortality caused by this parasitic disease. Many attempts* Correspondence: rm.olivia@gmail.com
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distribution, and reproduction in any mediumhave been made to generate a vaccine using the T. cruzi
highly immunogenic surface antigens, recombinant anti-
gens, and recently, the administration of test plasmid
DNA encoding different genes has been investigated. The
results of these tests have varied from no protection
against the disease to the partial reduction of short-term
mortality and morbidity rates in a murine model [2-4].
Although there have been a number of successes using
this type of vaccine, it is necessary to improve the vaccine-
mediated immune response, to document the results in
detail, and to replicate the experiments in other species.
The canine model is ideal because dogs develop the signs
of the disease and immunopathological changes that are
similar in humans; in addition, dogs are consideredentral Ltd. This is an Open Access article distributed under the terms of the
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bute to the transmission of T. cruzi to humans; therefore,
a decrease in the incidence of the disease in this species
would have significant beneficial effects for humans [5-7].
In the case of Chagas disease, the cell-type immune
response plays a fundamental role because the parasite
exhibits an intracellular phase during the infection. One
of the best indicators of the establishment of a cellular
immune response is the production of type 1 cytokines,
whereas type 2 cytokines promote the antibody response.
It has been established that the predominance of Th1
cytokines is more effective in eliminating the parasite and
therefore, reduces parasitaemia during the acute phase. In
the later stages of the disease, Th1/Th2 cytokines are as-
sociated with the absence of symptoms and the apparent
integrity of the cardiac tissue [8,9]. Both cellular and
humoral immune responses are driven by CD4 + T lym-
phocytes (Th1 and Th2) through signals generated by cy-
tokines. In a previous study, a cDNA clone encoding the
amastigote-specific surface protein TcSSP4 was used as a
candidate gene to develop a DNA vaccine. The mice were
immunized with the recombinant protein rTcSSP4 and
with the TcSSP4 cDNA and were challenged with the
introduction of blood trypomastigotes. The immunization
with the rTcSSP4 protein rendered the mice more sus-
ceptible to trypomastigote infection and exhibited high
mortality rates, whereas the mice immunized with a
eukaryotic expression plasmid containing the TcSSP4
cDNA controlled the acute phase of the infection. Com-
pared with the control animals, the heart tissue of the
DNA-vaccinated animals did not demonstrate myocarditis
and tissue damage at 365 days following infection.
Interferon-gamma (IFN-γ) was detected in the sera of the
DNA-vaccinated mice shortly after immunization, sugges-
ting the development of a Th1 response. Therefore, the
TcSSP4 gene is a promising candidate for the development
of an anti-T. cruzi DNA vaccine [10].
In this study, the humoral and cellular immune re-
sponses were evaluated in dogs immunized with 2T. cruzi
genes, TcSP (gene encoding a member of the trans-
sialidase family that is present in all three forms of T. cruzi)
[11] and TcSSP4, through the measurement of antibodies
and cytokines in the serum, antibody-dependent cell lysis,
and the in vitro proliferation of the dog splenocytes.
Materials and methods
Animals
Male and female 4-month-old Beagle dogs (35 in total)
were purchased from Criadero El Atorón (Teotihuacán,
Estado de México; Mexico). All animals were subjected
to a physical examination and were quarantined. The
dogs were dewormed and vaccinated against the main
canine infectious diseases. The dogs were tested for the
absence of antibodies against T. cruzi using the (ELISA).The animals were handled in accordance with the guide-
lines established by international authorities and the
Norma Oficial Mexicana technical specifications for the
care and use of laboratory animals [12]. The Bioethics
Committee of the Instituto Nacional de Cardiología,
Ignacio Chávez approved the experimental protocol.
Immunization and challenge
The dogs were divided randomly into 5 groups (n = 7).
The groups were immunized with pBCSSP4, pBCSP,
pBk-CMV (empty plasmid) or saline solution (SS) (used
as a control), and 15 days after the last immunization,
the 4 groups were infected with the parasite. The two
plasmid constructs (pBCSSP4 and pBCSP) were gene-
rated and characterized as described previously [11]. The
immunizations consisted of 2 intramuscular injections of
500 μg of DNA dissolved in 500 μL of SS administered at
2-week intervals.
The parasites were obtained from urine and feces of
triatomes and resuspended in physiologic solution. The
animals in the fifth group were administered 500 000
metacyclic trypomastigotes intraperitoneally. All the ani-
mals survived the treatment and they are currently being
used in other studies. The challenge was performed
using the Ninoa strain of T. cruzi that was isolated from
a patient in Mexico [13] and was maintained by serial
passages in triatomines.
Parasitaemia
The parasitaemia was determined microscopically by
examining freshly isolated blood samples collected from
the brachiocephalic vein of the infected animals every
third day, starting on day 10 post-infection until day 65
post-infection.
T. cruzi anti-IgG determination using enzyme-linked
immunosorbent assay (ELISA)
A standardized ELISA to detect the anti T. cruzi anti-
body using as the antigen a total extraction of T. cruzi
INC-9 isolate of epimastigote forms [14] was performed
to rule out any previous natural infections in all dogs, to
establish the production of antibodies following immu-
nization in immunized/non-infected dogs, and to confirm
the experimental infection two months after challenge in
all infected/unimmunized dogs.
Indirect immunofluorescence (IIF) assay
The ELISA-reactive sera were processed by IIF using the
method described as follows: INC-9 T. cruzi epimas-
tigote suspension was placed on a slide and fixed. A 1:40
dilution of the test serum was made in 1X phosphate
buffered saline (PBS), incubated in a humidified chamber
at room temperature for 1 h, and washed under stirring
in PBS three times (5 min for each wash). The slides
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escein isothiocyanate- labeled goat anti-dog IgG conjugate
(Novus Biologicals). The slides were examined with a UV
epifluorescence microscope at 3200 and 3400 magnifica-
tion for specific trypanosomal fluorescence. Positive fluo-
rescence was defined as detection of green fluorescence
on parasites and was labeled with + /+ + + + according to
the fluorescence degree watched, using a positive control
as the reference point [14].
Complement-mediated lysis assay
The metacyclic trypomastigotes were obtained from the
urine and feces of triatomines and were resuspended in
SS; 2 × 104 parasites were incubated with 5 μL healthy
dog sera or test serum (immunized/non-infected dogs)
for 1 h at 37°C. Guinea pig complement (25 μL) (Faculty
of Veterinary Medicine, Universidad Nacional Autónoma
de México) was added, and the tubes were incubated for
2 h at 37°C. The control tubes contained parasites incu-
bated with test serum and heat-inactivated complement
(56°C for 30 min), and parasites incubated with pre im-
mune serum and complement. The samples were assayed
in triplicate, and the number of motile trypomastigotes
was determined using a hemocytometer. The percentage
of antibody-dependent cell lysis was calculated by deter-
mining the percent killing = 100 – [(number of parasites
after incubation with guinea pig complement/number of
parasites after treatment with heat-inactivated comple-
ment) × 100], as previously reported [15].
Cytokine analysis
The cytokine levels in the sera of immunized dogs at 12
and 24 h after the last immunization, or 9 months after
the infection, were measured using ELISA. The ELISA
for IFN-γ, interleukin-10 (IL-10) and tumor necrosis
factor-alpha (TNF-α) were performed in accordance
with the manufacturer’s instructions (Preprotech, Rocky
Hill, NJ, USA).
Cell proliferation assay
On day 15 after the last DNA immunization or SS inocu-
lation, and before the challenge, a partial splenectomy was
performed [16]. The canine spleen cells were washed 3
times in Hank’s solution (Sigma Aldrich, St. Louis, MO,
USA) and were resuspended in Dulbecco’s Modified Eagle
Medium (DMEM, Gibco BRL) supplemented with
2 mM L-glutamine, 50 μM β−Mercaptoethanol, 1%
(vol/vol) non-essential amino acid solution and 10% fetal
bovine serum, to a concentration of 4 × 105 cells/mL. The
assay was performed in 96-well flat bottom plates
(Corning); 100 μL of the cell suspension was placed into
each well, and the total parasite extract of epimastigote
forms was added to a concentration of 10 μg/mL. Conca-
navalin A (Con A) (Sigma Aldrich, St. Louis, MO, USA)was added to a concentration of 2 μg/mL as a positive
control. Each determination was performed in duplicate.
The cultures were incubated at 37°C in 5% CO2 for 120 h
(or 72 h for Con A). At 16 h prior to the end of the incu-
bation, 0.5 μCi of [3H]-thymidine (Amersham) were added
to each well. The lymphocytes were collected using a
manual cell harvester, and the amount of incorporated
radioactive thymidine was measured using liquid scintilla-
tion spectroscopy (Beckman, LS 5801). The stimulation of
a specific cellular immune response is represented by the
stimulatory index (S.I.) [17].
Statistical analysis
All the data were analyzed using one-way ANOVA sta-
tistics followed by Tukey’s analysis. In all cases, diffe-
rences were considered significant when P < 0.05.
Results
Parasitaemia and establishment of infection
All of the experimental animals tested negative in the
ELISA prior to the start of the experiment.
All unimmunized/infected dogs exhibited parasitaemia
starting on day 22 and lasting until day 51 post-infection,
whereas the parasitaemia in the immunized/infected
dogs was for a shorter period, from day 32 to 46 post-
infection (Table 1). Parasitaemia was too low to be
quantified, and parasites were only seen by direct obser-
vation. The limit of detection was 200 to 400 parasites/
mL of blood sample intermittently throughout all analysis.
At two months post-inoculation, the T. cruzi infection was
diagnosed by the ELISA method and was confirmed by IIF
in all unimmunized/infected dogs (data not shown). All
animals survived the infection with the parasite, because
the strain used is not lethal. However, these dogs showed
cardiopathy demonstrated in electrocardiographic studies
such as left ventricle enlargement, intraventricular con-
duction defects, right bundle branch block and ventricular
premature complexes. In immunized/infected dogs, the
quality and quantity of the electrocardiographic abnormal-
ities diminished [11].
Humoral immune response
Determination of the parasite-specific immunoglobulin G
(IgG) antibodies using ELISA revealed that immunization
with both recombinant plasmids induced a significant pro-
duction of IgG against the parasite 15 days after the last
immunization (immunized/non-infected dog determina-
tion of the parasite-specific immunoglobulin G (IgG) anti-
bodies using ELISA revealed that immunization with both
recombinant plasmids induced a significant production of
IgG against the parasite 15 days after the last immunization
(immunized/non-infected dogs). As shown in Figure 1B,
ELISA analysis shows that recombinant plasmid immu-
nized/non-infected dogs displayed T. cruzi-specific IgG1
Table 1 Parasitemia detection in DNA-immunized dogs with experimental T. cruzi infection
Group Dog Days after inoculation
10-15 16-20 21-25 26-30 31-35 36-40 41-45 46-50 51-60 6165












pBk-CMV 1 + +





SS mock-immunized 1 + + + + +
2 + +
3 + + + + + +
4 + +
5 + + + + + +
6 + + + + +
+ Detection of 1 or 2 parasites per blood sample of fresh drop examination.
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inoculated/non-infected and pBk-CMV-immunized/non-
infected dogs.
The DNA immunization with recombinant plasmids
induced a predominant Th1 type antibody response be-
cause of the IgG produced, the majority belonging to the
IgG2 subclass and to a lesser extent, to the IgG1 sub-
class (Figure 1C).
As expected, all dogs exhibited high levels of anti-
bodies against T. cruzi after challenge (Figure 1).Complement-mediated lysis
To assess the biological activities of the antibodies induced
by the DNA immunization, we performed complement-
mediated parasite lysis assays. The sera of dogs immu-
nized with the recombinant plasmids were in contact with
the metacyclic trypomastigotes and guinea pig comple-
ment. The antibodies produced by the dogs immunized
with the recombinant plasmids induced the complement-
mediated lysis of trypomastigotes in vitro. The specificlysis of parasites was not detected when the pre immune
serum or the serum from dogs immunized with the con-
trol empty plasmid or SS were used.
Treating the parasites with the serum from the dogs
immunized with pBCSSP4 or pBCSP plasmids resulted
in 68% (± 21.4) and 54% (± 11.8) lysis, respectively
(Figure 2); the results with both plasmids were similar.Cytokine quantification
The DNA vaccines tested did not generate increased cy-
tokines at 12 h post immunization; however, at 9 months
post-infection, although both DNA vaccines were tested,
only the pBCSSP4 plasmid induced a significant increase
in IFN-γ (1080 pg/mL ± 100) and IL-10 (800 pg/mL ±
102) levels in the dogs (Figure 3) at this same time, the
values obtained with the pBCSP plasmid-immunization
for IFN-γ (100 pg/mL ± 20), IL-10 (102 pg/mL ± 68),
and TNF-α (221 pg/mL ± 15) were similar to those ob-
































































































Figure 1 The antibody response to T. cruzi infection in
immunized dogs. An ELISA was performed to evaluate the serum
levels (absorbance in optical density at 405 nm) of T. cruzi-specific
antibodies at different times. (A) IgG, (B) IgG1, and (C) IgG2. To
determine all immunoglubulins, 1 μg/μL of total T. cruzi extract was
used, and the anti-dog IgG, IgG1 and IgG2 antibodies (Novus
Biologicals) were diluted 1: 10 000 (IgG), 1:5000 (IgG1) and 1:30 000
(IgG2) in blocking buffer. Pre imm: before the immunization, Post
imm: 15 days after the last immunization, and Imm & inf: 60 days
after the infection in immunized dogs. The values represent the
average of triplicate assays ± S.D (* P < 0.05).
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To evaluate the specific cellular immune response
in the dogs immunized intramuscularly with the
genes from T. cruzi (the dogs were not infected), westudied the lymphoproliferative response to the para-
site antigens.
Con A was used as a positive control; since in the
presence of a nonspecific mitogen, the cells necessarily
proliferate if they are viable.
Positive lymphoproliferative responses were observed in
the animals immunized with the T. cruzi genes. The highest
lymphocyte S.I. (3.99) was observed in the dogs immunized
with the pBCSP plasmid, and although there was less pro-
liferation in the splenocytes from the dogs immunized with
pBCSSP4, the S.I. (2.6) was positive (Figure 4), showing a
value above 2.0 when the lymphocyte cultures were stimu-
lated with the parasite antigens. In the other groups (con-
trols) there was no cell proliferation; the S. I. values were
below 2.0. The cultures stimulated with Con A showed a
mean S. I. value of 5.99 ± 2.05 demonstrating the cell via-
bility in all experimental groups. These results suggest that
the administration of nucleic acids from T. cruzi induces
the specific stimulation of the cellular immune response.
Discussion
In animal models, it has been shown that DNA
immunization induces and modulates the immune re-
sponse necessary for the prevention of infectious dis-
eases [18], for the treatment of neoplastic disorders [19]
and for allergic treatment [20] and autoimmune diseases
[21]. Therefore, we employed this method of im-
munization to induce a specific immune response
against T. cruzi in Beagle dogs.
Antibodies may contribute to the immunity against T.
cruzi through complement-dependent cytolysis, opsonic
and/or cytophilic antibodies that enhance phagocytosis in
antibody-dependent cellular lysis reactions against the
parasite, and possibly by interfering with the physiologic
processes of the parasite. Generally, polyclonal B cell
activation that leads to hypergammaglobulinemia and a
delayed specific humoral immune response is accepted as
a characteristic of acute phase Chagas disease in humans
and is reported in rodent experimental models of T. cruzi
infection [22,23]. Different IgG isotypes have been impli-
cated in polyclonal B cell activation and parasitic-specific
antibody responses; the major antibody isotypes involved
in the elimination of parasite blood forms and in decrea-
sing mortality rates are IgG1 and IgG2 [24,25].
The analysis of the IgG subclasses produced by the
immunization of canines with both recombinant plas-
mids revealed that the dominant antibody produced was
IgG2; in a previous study in mice immunized with the
pBCSP plasmid, the dominant subclass was also IgG2a
[26]. These results are consistent with other studies
using DNA vaccines; for example, the majority of anti-
bodies produced were of the IgG2 subclass following
immunization of dogs with a multi-component DNA


























Figure 3 Cytokine response in pBCSSP4- and pBCSP-immunized dogs
and TNF-α at different times. Pre immune: before the immunization, Post im




























Figure 2 Percentage of complement-mediated lysis of
trypomastigotes. Percent killing = 100 – [(number of parasites after
incubation with guinea pig complement/number of parasites after
treatment with heat-inactivated complement) × 100]. Inactivated-
complement: test serum (post immune obtained 15 days after the last
immunization) and heat-inactivated complement (56°C for 30 min), Pre
immune: sample obtained before the immunization and complement,
and Post immune: test serum (obtained 15 days after the last
immunization) and complement. All dogs were non-infected. The
values represent the average of triplicate assays ± S.D (* P < 0.05).
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Chioccola et al., mice were immunized with a plasmid
containing the trans-sialidase gene, and the majority of the
antibodies produced were of the IgG2a subclass, whereas
following immunization with the recombinant protein, the
dominant antibody subclass was IgG1 [28]. Because the
subclass profile of antibodies reflects the type of activated
helper T cells [29], the predominant IgG2 subclass pro-
duction after plasmid vaccination with both genes in this
study suggests a Th1 skewed response.
Various antibodies against Trypanosoma cruzi elicited
by an active infection may have different functional ac-
tivities. Antibodies that bind to live trypomastigote
forms and lyse them in conjunction with complement in
an in vitro reaction have been linked to active infection.
These lytic antibodies, detected by the complement-
mediated lysis test, are produced after infection, and
have been used to evaluate treatment efficacy in Chagas’
disease in which the negative result of the complement-
mediated lysis test has been interpreted as the absence
of parasitemia and a cure. The Zulantay et al. results
support the idea of the role of lytic antibodies in the
control of parasitemia [30]. Lytic antibodies are not easy
to elicit by immunization with dead parasite or with
purified T. cruzi antigens, although they are readily
detected in mice, rats, rabbits and humans infected with
the parasite [31]. The present study indicates that
immunization with pBCSP and pBCSSP4 plasmids in-
duced the humoral immune response and that such anti-
bodies mediated the lysis of parasites through the







. An ELISA was performed to evaluate the serum levels of IFN-γ, IL-10,
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Figure 4 Spleen lymphocyte proliferation in immunized dogs.
The values represent the S.I. estimated as follows: mean counts per
minute of stimulated cultures/mean counts per minute of non-
stimulated cultures. S.I. values equal to or above 2.0 were considered
positive (+). Con A: concanavalin A and Ag: parasite total protein
extract of epimastigote forms.
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with protection. Our data are comparable to results
reported by Sepúlveda et al. showing that the immu-
nization of mice with DNA encoding a regulatory pro-
tein of the complement pathway of T. cruzi, protected
against lethal challenge in a process that involved lytic
antibodies [15]. It has been shown that the susceptibility
of T. cruzi to lysis by complement varies according to
the strain [32]; complement lysis assays showed that the
Colombian T. cruzi strain is more susceptible to lysis
than the Y T. cruzi strain at all serum concentrations
[33]. Indeed, even within the same strain, variations in
susceptibility have been observed among different clones
[34]. There are no reports of T. cruzi lysis by complement
with Ninoa strain; in our study the results showed a high
percentage of lysis, similar to other Mexican Trypanosoma
cruzi isolates reported by other authors [32].
The vaccination regimen used in our experimental
model induced a cell-mediated immunity characterized by
lymphoproliferation, as well as the enhanced production
of IFN-γ, which was in agreement with the results from
Cazorla et al. who studied mice immunized with a T. cruzi
recombinant cruzipain (rCz); they measured the abun-
dance of rCz-specific IFN-γ secreting- CD8+ T-cells in
splenocytes depleted of CD4+ lymphocytes, and survival,
efficient control of parasite load and restricted inflamma-
tory myopathy were demonstrated [35]. Therefore, our
experimental immunization appears promising for the de-
velopment of a vaccine that generates similar results, since
one of our antigens (TcSP) is an enzyme that is expressed
in all developmental forms of the parasite (epimastigote,
amastigote and trypomastigote) and it is also present at
the surface level, characteristics shared with cruzipain.
Previously, immunization with the pBCSSP4 plasmid
in a murine model induced significant amounts of IFN-γat 3 hours post immunization, and significant amounts
of IL-6 and TNF-α at 3 and 12 h post immunization
[10]; however, in our canine model, immunization with
pBCSSP4 or pBCSP did not induce cytokine production
at 12 h post immunization. At 9 months after infection
with T. cruzi in the dogs previously vaccinated with the
pBCSSP4 plasmid, high levels of IFN-γ (1080 pg / mL)
were observed and TNF-α was present to a lesser extent.
These results together with the high production of
IgG2a subclass indicate a Th1 pattern, and were con-
sistent with reports from Aparicio-Burgos et al.; the
circulatory cytokine levels (IFN-γ and IL-10) were below
the detection limits before and after immunization with
a multi-component DNA-prime/DNA-boost vaccine
TcVac1— vaccine constituted of antigen-encoding plas-
mids (pCDNA3.TcG1, pCDNA3.TcG2 and pCDNA3.
TcG4) and IL-12- and GMCSF-expression plasmids—,
and all the dogs responded to infection with increases in
IFN-γ levels (580 pg/mL approximately at 15 days post
infection) [27].
During the testing of a therapeutic DNA vaccine en-
coding the TSA-1 antigen of T. cruzi in a murine model,
the immunized mice exhibited significant increases in
CD4 and CD8 T cells producing IFN-γ during the
chronic phase of infection. This increase in IFN-γ pro-
duction was associated with reduced inflammation of
the cardiac tissue and a reduction in the parasite load
[36]. Moreover, immunization with pELI_Tc2 (DNA
from T. cruzi) produced elevated levels of IFN-γ that
were associated with lower parasite loads after challenge
[37]. In accordance with these results, the present study
demonstrates that the recombinant plasmid vaccination
induced high levels of IFN-γ, shorter parasitaemia, lower
parasite load and also cardiac and clinical protection in
immunized/infected dogs, the latter recently reported by
Rodríguez-Morales et al. [11].
In dogs at the late stage of infection with T. cruzi cha-
racterized by the absence of heart damage, high levels of
IL-10 in the serum and supernatants of peripheral blood
mononuclear cells have been observed [7]. The signifi-
cant increase in IFN-γ and IL-10 in the group immu-
nized with the pBCSSP4 plasmid is attributed to the
TcSSP4 gene, or to the combination of this gene and the
presence of the parasite (or the parasite antigenic mole-
cules). The increase in IFN-γ and IL-10 cannot be due
to the infection alone because an increase in the syn-
thesis of the cytokines was not observed in the other
infected groups. Therefore, immunization modulates the
pattern of cytokine expression in infected dogs.
The results presented in this study support DNA
immunization as a strategy for designing anti-T. cruzi
vaccines. It was demonstrated that this type of vaccine
effectively induces antigen-specific antibodies and pro-
duces a Th1-type cellular immune response reflected in
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Chagas disease because this strategy 1) avoided acute
phase fever, 2) induced an immune response that
manifested as lymph node enlargement as part of host-
protective activity, 3) avoided heart rate increases during
the acute and/or chronic stages, and 4) most interes-
tingly, halted the symptomatic progression to severe
heart conduction abnormalities [11].
These vaccines will allow us to determine if this immune
response confers protection against acute and chronic T.
cruzi infection, the course of the infection, the patho-
logical variables, and the clinical status in Beagle dogs with
experimentally induced trypanosomiasis.
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